Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255706908> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4255706908 endingPage "5132" @default.
- W4255706908 startingPage "5132" @default.
- W4255706908 abstract "5132 Background: In a previous study (Marinaccio et al. Proc.ASCO 2003;Abstr1952) we assumed that pretreatment normalization of mild anemia with epoetin alfa could improve the outcome in patients with epithelial ovarian cancer. The aim of this larger trial was to understand better the influence of recombinant human erythropoietin (rHuEPO) on the outcome of ovarian cancer patients showing anemia before undergoing surgery and chemotherapy. Methods: Between 1999 and 2003, 42 patients with mild anemia (Hgb 10.6–11.9 g/dL) secondary to advanced epithelial ovarian cancer were randomized to receive epoetin alfa (21 pts.) or not (21 pts.) before primary surgery. All patients were without past or present second malignancy and aged less than 76 years. FIGO stage at diagnosis was as follows: IC 13/42; II 5/42; III 19/42; IV 5/42. After surgery all patients underwent adjuvant chemotherapy with paclitaxel (175mg/mq) plus carboplatin (AUC5). Patients in the treatment group were administered rHuEPO, 10.000 IU, three times a week subcutaneously for 4–6 weeks. The patients receiving rHuEPO had a significantly greater increase in hematocrit and Hgb compared with the control group (p<0.01). Survival curves were described by Kaplan-Meier method. The relationship of Hgb to survival was determined by Cox Regression analysis after adjusting for the effect of known prognostic variables including FIGO stage, tumor grade and residual tumor. Results: The mean age of patients was 54.1 years. The median duration of follow-up was 30 months. The median relapse-free survival time was found to be 26 months in patients treated with rHuEPO and 18 months in the control arm; the evaluation of median survival time is in progress, however Kaplan-Meier 12-month estimates of survival were 65% for the rHuEPO arm and 50 % for the control arm, revealing a trend in overall survival favoring normalization of pre-treatment anemia with rHuEPO (Kaplan-Meier analysis p=0.12, Cox regression analysis p=0.044). Conclusions: Pretreatment of mild anemia with epoetin alfa in patients with epithelial ovarian cancer offers an excellent possibility of improving the outcome. No significant financial relationships to disclose." @default.
- W4255706908 created "2022-05-12" @default.
- W4255706908 creator A5028591230 @default.
- W4255706908 creator A5035909257 @default.
- W4255706908 creator A5054090202 @default.
- W4255706908 creator A5069960249 @default.
- W4255706908 creator A5086761043 @default.
- W4255706908 creator A5087647292 @default.
- W4255706908 date "2004-07-15" @default.
- W4255706908 modified "2023-09-25" @default.
- W4255706908 title "Pretreatment normalization of mild anemia with epoetin alfa predicts long-term outcome for women with epithelial ovarian cancer" @default.
- W4255706908 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.5132" @default.
- W4255706908 hasPublicationYear "2004" @default.
- W4255706908 type Work @default.
- W4255706908 citedByCount "0" @default.
- W4255706908 crossrefType "journal-article" @default.
- W4255706908 hasAuthorship W4255706908A5028591230 @default.
- W4255706908 hasAuthorship W4255706908A5035909257 @default.
- W4255706908 hasAuthorship W4255706908A5054090202 @default.
- W4255706908 hasAuthorship W4255706908A5069960249 @default.
- W4255706908 hasAuthorship W4255706908A5086761043 @default.
- W4255706908 hasAuthorship W4255706908A5087647292 @default.
- W4255706908 hasConcept C121608353 @default.
- W4255706908 hasConcept C126322002 @default.
- W4255706908 hasConcept C141071460 @default.
- W4255706908 hasConcept C143998085 @default.
- W4255706908 hasConcept C146357865 @default.
- W4255706908 hasConcept C151730666 @default.
- W4255706908 hasConcept C2776164570 @default.
- W4255706908 hasConcept C2776694085 @default.
- W4255706908 hasConcept C2778239845 @default.
- W4255706908 hasConcept C2778248108 @default.
- W4255706908 hasConcept C2778534260 @default.
- W4255706908 hasConcept C2780427987 @default.
- W4255706908 hasConcept C2781451048 @default.
- W4255706908 hasConcept C71924100 @default.
- W4255706908 hasConcept C86803240 @default.
- W4255706908 hasConcept C90924648 @default.
- W4255706908 hasConceptScore W4255706908C121608353 @default.
- W4255706908 hasConceptScore W4255706908C126322002 @default.
- W4255706908 hasConceptScore W4255706908C141071460 @default.
- W4255706908 hasConceptScore W4255706908C143998085 @default.
- W4255706908 hasConceptScore W4255706908C146357865 @default.
- W4255706908 hasConceptScore W4255706908C151730666 @default.
- W4255706908 hasConceptScore W4255706908C2776164570 @default.
- W4255706908 hasConceptScore W4255706908C2776694085 @default.
- W4255706908 hasConceptScore W4255706908C2778239845 @default.
- W4255706908 hasConceptScore W4255706908C2778248108 @default.
- W4255706908 hasConceptScore W4255706908C2778534260 @default.
- W4255706908 hasConceptScore W4255706908C2780427987 @default.
- W4255706908 hasConceptScore W4255706908C2781451048 @default.
- W4255706908 hasConceptScore W4255706908C71924100 @default.
- W4255706908 hasConceptScore W4255706908C86803240 @default.
- W4255706908 hasConceptScore W4255706908C90924648 @default.
- W4255706908 hasIssue "14_suppl" @default.
- W4255706908 hasLocation W42557069081 @default.
- W4255706908 hasOpenAccess W4255706908 @default.
- W4255706908 hasPrimaryLocation W42557069081 @default.
- W4255706908 hasRelatedWork W1481820868 @default.
- W4255706908 hasRelatedWork W1968089756 @default.
- W4255706908 hasRelatedWork W2010230997 @default.
- W4255706908 hasRelatedWork W2070587601 @default.
- W4255706908 hasRelatedWork W2072767112 @default.
- W4255706908 hasRelatedWork W2320097775 @default.
- W4255706908 hasRelatedWork W2391154258 @default.
- W4255706908 hasRelatedWork W2417634857 @default.
- W4255706908 hasRelatedWork W2471989939 @default.
- W4255706908 hasRelatedWork W2418834791 @default.
- W4255706908 hasVolume "22" @default.
- W4255706908 isParatext "false" @default.
- W4255706908 isRetracted "false" @default.
- W4255706908 workType "article" @default.